Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Stocks in play: Oncolytics Biotech Inc

Baystreet.ca - Baystreet - Tue Nov 12, 9:38AM CST

Today announced third quarter financial results and operational highlights. Highlights include BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study. Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort. Oncolytics Biotech Inc shares T.ONC are trading down one cent at $1.48.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).